• 17 MAR 14

    Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.

    Autori

    Maiolino G, Pedon L, Cesari M, Frigo AC, Wolfert RL, Barisa M, Pagliani L, Rossitto G, Seccia TM, Zanchetta M, Rossi GP.

    Abstract

    OBJECTIVE:

    Lipoprotein-associated phospholipase A2 (Lp-PLA2) is deemed to play a role in atherosclerosis and plaque destabilization as demonstrated in animal models and in prospective clinical studies. However, most of the literature is either focused on high-risk, apparently healthy patients, or is based on cross sectional studies. Therefore, we tested the hypothesis that serum Lp-PLA2 mass and activity are useful for predicting cardiovascular (CV) events over the coronary atherosclerotic burden and conventional risk factors in high-risk coronary artery disease patients.

    METHODS AND RESULTS:

    In a prospective cohort study of 712 Caucasian patients, who underwent coronary angiography and measurement of both Lp-PLA2 mass and activity at baseline, we determined incident CV events at follow-up after splitting the patients into a high and a low Lp-PLA2 mass and activity groups based on ROC analysis and Youden index. Kaplan-Meier and propensity score matching analysis were used to compare CV event-free survival between groups. Follow-up data were obtained in 75% of the cohort after a median of 7.2 years (range 1-12.7 years) during which 129 (25.5%) CV events were observed. The high Lp-PLA2 activity patients showed worse CV event-free survival (66.7% vs. 79.5%, p = 0.023) and acute coronary syndrome-free survival (75.4% vs. 85.6%, p = 0.04) than those in low Lp-PLA2 group.

    CONCLUSIONS:

    A high Lp-PLA2 activity implies a worse CV prognosis at long term follow up in high-risk Caucasian patients referred for coronary angiography.

    Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.

Contatti

Per informazioni è possibile contattarci ai seguenti recapiti:

  • Email: foricaonlus.padova@gmail.com

  • Tel.: +39 049-821-2260

  • Tel: +39 049-821-2279

  • Fax: +39 049-875-4179

Dona ora

Il tuo contributo è prezioso per sostenere la ricerca cardiovascolare dei nostri ricercatori, e per diffondere nella popolazione la conoscenza del problema “ipertensione”. Ciò permette di evitare che molte persone, spesso giovani, incorrano nelle temibili complicanze dell’Ipertensione Arteriosa non diagnosticata in tempo.